96 related articles for article (PubMed ID: 19525681)
1. Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Haas S
Eur J Haematol; 2009 May; 82(5):339-49. PubMed ID: 19187276
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency.
Yamaguchi J; Hara N; Yamaguchi T; Nagata Y; Nozato T; Miyamoto T
J Cardiol Cases; 2017 Nov; 16(5):144-147. PubMed ID: 30279820
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Mavromanoli AC; Barco S; Konstantinides SV
Res Pract Thromb Haemost; 2021 May; 5(4):. PubMed ID: 34027284
[TBL] [Abstract][Full Text] [Related]
4. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Rachidi S; Aldin ES; Greenberg C; Sachs B; Streiff M; Zeidan AM
Expert Rev Hematol; 2013 Dec; 6(6):677-95. PubMed ID: 24219550
[TBL] [Abstract][Full Text] [Related]
5. Deep vein thrombosis: a clinical review.
Kesieme E; Kesieme C; Jebbin N; Irekpita E; Dongo A
J Blood Med; 2011; 2():59-69. PubMed ID: 22287864
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular drug therapy in the elderly: benefits and challenges.
Fleg JL; Aronow WS; Frishman WH
Nat Rev Cardiol; 2011 Jan; 8(1):13-28. PubMed ID: 20978470
[TBL] [Abstract][Full Text] [Related]
7. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
10. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Chen T; Lam S
Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
